U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H21N5O5
Molecular Weight 351.3577
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GR-79236

SMILES

OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CN=C3N[C@H]4CCC[C@@H]4O

InChI

InChIKey=GYWXTRVEUURNEW-TVDBPQCTSA-N
InChI=1S/C15H21N5O5/c21-4-9-11(23)12(24)15(25-9)20-6-18-10-13(16-5-17-14(10)20)19-7-2-1-3-8(7)22/h5-9,11-12,15,21-24H,1-4H2,(H,16,17,19)/t7-,8-,9+,11+,12+,15+/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H21N5O5
Molecular Weight 351.3577
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

GR79236 is an adenosine A1 receptor agonist, which possesses cardiovascular and antilipolytic properties. GR79236 was studied in model animals for the treatment of diabetic ketoacidosis and in patients for pain relief. However, these studies were discontinued. In addition, analgesic efficacy of GR79236 was investigated in the dental pain model. Nevertheless, there was no evidence of efficacy of GR79236. A higher dose of GR79236 might have been effective or that was suggested, that intravenous administration of that drug did not achieve appropriate concentrations in the brain or peripheral nerves.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

Seventy-nine patients with moderate pain after third molar extraction under general anaesthesia were randomized to receive a 15 min double-blind infusion containing either GR79236X 4 microg kg-1, GR79236X 10 microg kg-1, diclofenac 50 mg, or saline placebo. Rescue analgesia was promptly available to all patients.
Route of Administration: Intravenous
In Vitro Use Guide
In the presence of adenosine deaminase (ADA), GR79236 increased insulin sensitivity of pyruvate release from rat soleus muscle strips by 24% from 82.5 +/- 10.0 to 102.5 +/- 10.0 (P < 0.01), by 27% to 105.0 +/- 12.5 (P < 0.01) and by 24% to 102.5 +/- 10.0 (P < 0.01) nmol/25 mg per h at 0.1 and 10 microM GR79236, respectively. Rates of lactate release followed a similar but non-significant trend. Addition of GR79236 in the presence of ADA had no effect on rates of glycogen synthesis.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:33:40 GMT 2023
Edited
by admin
on Fri Dec 15 16:33:40 GMT 2023
Record UNII
Q4H682B2VZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GR-79236
Common Name English
ADENOSINE, N-(2-HYDROXYCYCLOPENTYL)-, (1S-TRANS)-
Systematic Name English
N-((1S,TRANS)-2-HYDROXYCYCLOPENTYL)ADENOSINE
Systematic Name English
ADENOSINE, N-((1S,2S)-2-HYDROXYCYCLOPENTYL)-
Systematic Name English
GR79236
Common Name English
Code System Code Type Description
FDA UNII
Q4H682B2VZ
Created by admin on Fri Dec 15 16:33:40 GMT 2023 , Edited by admin on Fri Dec 15 16:33:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID10154427
Created by admin on Fri Dec 15 16:33:40 GMT 2023 , Edited by admin on Fri Dec 15 16:33:40 GMT 2023
PRIMARY
PUBCHEM
9884817
Created by admin on Fri Dec 15 16:33:40 GMT 2023 , Edited by admin on Fri Dec 15 16:33:40 GMT 2023
PRIMARY
CAS
124555-18-6
Created by admin on Fri Dec 15 16:33:40 GMT 2023 , Edited by admin on Fri Dec 15 16:33:40 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Rat brain receptor
BINDING
Ki
OFF TARGET->WEAK AGONIST
Rat brain receptor
BINDING
Ki
Related Record Type Details
ACTIVE MOIETY